Nut consumption (>3 times per week) was associated with a 39% reduction of all-cause mortality in the PREDIMED randomized trial.
This was in comparison to people in the trial who did not consume nuts.
The 7500 person trial ran for 4.8 years, and was designed as a primary prevention trial for CVD. The trial compared a control diet (similar to AHA recommendations at the time, a Mediterranean diet + extra EVOO, and a Mediterranean diet + nuts.
Participants who also consumed a traditional Mediterranean diet, along with nuts >3x per week, saw a whopping 63% reduction in total mortality, compared to people in the trial who did not consume nuts.
Not only was there a protective effect against dying of CVD from nut consumption, but there was a similar protective effect against dying of cancer.
Participants in the upper category of nut consumption had a 55% reduction in cardiovascular mortality and a 40% reduction in cancer mortality, compared to participants who did not consume nuts.
Note that these mortality results are from a prospective observational analysis of the trial cohort. As with all observational analyses, they do not prove causality.
As mentioned previously, nut consumption reversed arterial plaque in the carotid artery in this same trial:
↪ PREDIMED: nuts regressed carotid plaque and a nut-rich Mediterranean diet cut stroke 50%.
People in the nut group saw a large 50% reduction in risk of stroke, consistent with the reversal of plaque in the carotid:
This reduction in plaque and strokes was seen in the randomized trial itself, and was therefore proven causal.
Quoted:
“During a median follow-up of 4.8 years, 323 total deaths, 81 cardiovascular deaths and 130 cancer deaths occurred. Nut consumption was associated with a significantly reduced risk of all-cause mortality (P for trend <0.05, all). Compared to non-consumers, subjects consuming nuts >3 servings/week (32% of the cohort) had a 39% lower mortality risk (hazard ratio (HR) 0.61; 95% CI 0.45 to 0.83). A similar protective effect against cardiovascular and cancer mortality was observed. Participants allocated to the Mediterranean diet with nuts group who consumed nuts >3 servings/week at baseline had the lowest total mortality risk (HR 0.37; 95% CI 0.22 to 0.66).”
“Compared to non-consumers, subjects who consumed >3 servings of nuts per week at baseline had a significant 39% lower risk of all-cause mortality. Relative risk reductions were similar for the upper baseline category of non-walnut nuts (34%) or walnut consumption (45%), and when we evaluated the repeated measurements of total nut consumption over time (32%).
Moreover, those in the upper category of baseline nut consumption had a 55% lower risk of cardiovascular mortality and 40% lower risk of cancer mortality compared to those who never consumed nuts. The study subjects participated in the PREDIMED study, a long-term, randomized nutrition intervention trial [14], and those consuming more nuts at baseline and allocated to intervention with a MedDiet supplemented with nuts showed a significantly reduced total mortality risk of 63%.”
“Conclusion- Increased frequency of nut consumption was associated with a significantly reduced risk of mortality in a Mediterranean population at high cardiovascular risk.”
Paper · BMC Med · 2013Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial.Conclusion: Increased frequency of nut consumption was associated with a significantly reduced risk of mortality in a Mediterranean population at high cardiovascular risk.Please see related commentary: http://www.biomedcentral.com/1741-7015/11/165.pmc.ncbi.nlm.nih.gov

